For comparison, Forxiga (known as Farxiga in the US) was shown in the DAPA-CKD to cut by 39% the risk of kidney disease progression, or death from kidney or cardiovascular causes. The new approval ...

Forxiga was approved for CKD on the strength of the DAPA-CKD trial, which found that adding the drug to standard care in people with CKD reduced the risk of worsening renal function, the onset of ...

Based on genome-wide association study data from 2.2 million individuals, a functional prioritization scorecard integrates classical omics with allele-specific gene expression, chromatin ...